Blood Coagulation Disorders |
FAST, NCT02611973: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia |
|
|
| Recruiting | 3 | 2250 | Europe | Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm, Hydroxyurea treatment (HU) | Assistance Publique - Hôpitaux de Paris | MPN, Essential Thrombocythemia | 11/19 | 11/22 | | |
| Active, not recruiting | 3 | 4420 | Europe | Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) | University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen | Multiple Myeloma | 12/21 | 12/22 | | |
|
|
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma |
|
|
| Active, not recruiting | 1/2 | 56 | US | Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone | Cristina Gasparetto, Celgene | Multiple Myeloma | 12/16 | 01/25 | | |
TMI-ASCT, NCT00800059: Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 27 | Canada | Total Marrow Irradiation, TMI | Ottawa Hospital Research Institute | Multiple Myeloma | 11/20 | 11/25 | | |
NCT01250808: Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
|
| Available | N/A | | RoW | Bortezomib/Dexamethasone/Melphalan | Peking University | Multiple Myeloma | | | | |
NCT01701947: HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency |
|
|
| No Longer Available | N/A | | US | Hemoleven, Human Coagulation Factor XI | Laboratoire français de Fractionnement et de Biotechnologies | Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery | | | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib |
|
|
| No Longer Available | N/A | | US | Carfilzomib | University of Arkansas, Onyx Therapeutics, Inc. | Multiple Myeloma | 04/15 | 04/15 | | |
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Elotuzumab, BMS-901608 | Sundar Jagannath, Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients |
|
|
| No Longer Available | N/A | | Canada | bortezomib, melphalan, prednisone | Janssen-Ortho Inc., Canada, Ortho Biotech Canada | Multiple Myeloma | | | | |
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Panobinostat | Novartis Pharmaceuticals | Multiple Myeloma | | | | |
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron | Dana-Farber Cancer Institute, Bristol-Myers Squibb | Multiple Myeloma in Relapse, Multiple Myeloma | | | | |
| Recruiting | N/A | 10 | US | 124I-PU-AD, PET Scan, Blood draws | Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc. | Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease | 04/18 | 08/18 | | |
CoMMpass, NCT01454297: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile |
|
|
| Completed | N/A | 1154 | Europe, Canada, US | | Multiple Myeloma Research Foundation, Translational Genomics Research Institute, Spectrum Health Hospitals, Van Andel Research Institute | Multiple Myeloma | 11/23 | 12/23 | | |
NCT02869555: Institut Paoli Calmettes Multiple Myeloma Database |
|
|
| Recruiting | N/A | 5000 | Europe | Data collection | Institut Paoli-Calmettes | Multiple Myeloma | 01/30 | 12/30 | | |